Most people consider mosquitoes to be a summertime pest – the unwelcome guest at the backyard barbecue. More concerning are the threats from disease-carrying mosquitoes, those that can potentially result in Dengue, West Nile, Yellow fever and Zika. And now media are reporting alarming cases of Eastern equine encephalitis (EEE) in the United States that have already killed at least three people and infected others.
The new president first joined the Rockville hospital’s leadership team in 2011.
Lockheed Martin recently signed a $3 million charitable commitment to the University of Maryland A. James Clark School of Engineering. The three-year contribution will be used to fund work-related to vertical takeoff and landing research at the school’s rotorcraft lab, and high-speed flight experiments reaching up to Mach 8, or 6,000 mph.
“I think most of you know how deeply I care for this city and its people, how much I love being part of a place with so much grit, and grace, and potential,” University of Maryland, Baltimore (UMB) President Jay A. Perman, MD, told several hundred members of the Downtown Partnership of Baltimore (DPOB) at the group’s annual meeting Sept. 12. “I can’t imagine a higher honor than being in a position to help Baltimore reach that potential, to help it become what we know it can be.”
The Maryland Momentum Fund has been successful in its first couple of years but needs to do a better job of marketing itself to all of the University System of Maryland’s institutions, the fund’s director told the system’s Board of Regents Thursday. The fund, which the system uses to invest in startups related to system institutions, has …
Pharmaceuticals have come a long way since the apothecary days of prescribing cocaine drops for toothaches, or dispensing tapeworm diet pills.
The University System of Maryland recently invested $250,000 in a University of Maryland alumna’s biotech company.
RegenxBio Inc. just locked in another deal — this one with a company working to treat eye diseases.
The Rockville biotech has reached a licensing agreement with Alpharetta, Georgia-based Clearside Biomedical Inc. (NASDAQ: CLSD) for rights to its platform to treat several eye diseases including wet age-related macular degeneration and diabetic retinopathy. RegenxBio (NASDAQ: RGNX) plans to evaluate one of its own gene therapy programs, called RGX-314, using Clearside’s in-office injection as an alternative to surgery.
With nothing more than a passing glance, the U.S. Food & Drug Administration’s (FDA) approval of Roche Holdings’ (OTC:RHHBY) cancer drug entrectinib last month was a run-of-the-mill announcement. In fact, it was almost boilerplate in its tone and feel.
A small clinical study in California has suggested for the first time that it might be possible to reverse the body’s epigenetic clock, which measures a person’s biological age.
For one year, nine healthy volunteers took a cocktail of three common drugs — growth hormone and two diabetes medications — and on average shed 2.5 years of their biological ages, measured by analysing marks on a person’s genomes. The participants’ immune systems also showed signs of rejuvenation.
